Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Biologicals ; 40(6): 415-20, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23040097

ABSTRACT

Challenge with live pathogens could be substituted by serology for many veterinary diseases, however little progress has been made in the development of alternative batch vaccine potency tests for fish. This study reports the development and preliminary validation of a single-dilution filtration-assisted chemiluminometric immunoassay (SD FAL-ELISA) applied to measure anti Piscirickettsia salmonis IgM in individual or pooled serum and mucus samples. The assay was set up to test a single-dilution of the sample. Serum SD FAL-ELISA yielded a sensitivity of 90% and a specificity of 96%. SD FAL-ELISA was applied to evaluate pooled and individual samples from P. salmonis challenge assessments. Relative-light units values (RLU) obtained by SD FAL-ELISA were proportional to antibody levels in serum. RLU values obtained from pooled and individual serum samples increased with the observed relative percent survival (RPS) values, indicating a correlation between protection and specific IgM levels. Results obtained for specific IgM in mucus samples was not related to the RPS, but discriminated the vaccine that yielded high RPS (86.4%) from the others (40.9 and 54.5%). This is the first report on the development of an indirect high-throughput serological assessment for P. salmonis vaccine potency testing using both pooled or individual serum and cutaneous mucus samples.


Subject(s)
Bacterial Vaccines/immunology , Enzyme-Linked Immunosorbent Assay/methods , Luminescence , Piscirickettsia/immunology , Animals , Reproducibility of Results
2.
Virus Genes ; 44(1): 32-9, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21858463

ABSTRACT

The continuous emergence of new strains of canine parvovirus (CPV), poorly protected by current vaccination, is a concern among breeders, veterinarians, and dog owners around the world. Therefore, the understanding of the genetic variation in emerging CPV strains is crucial for the design of disease control strategies, including vaccines. In this paper, we obtained the sequences of the full-length gene encoding for the main capsid protein (VP2) of 11 canine parvovirus type 2 (CPV-2) Argentine representative field strains, selected from a total of 75 positive samples studied in our laboratory in the last 9 years. A comparative sequence analysis was performed on 9 CPV-2c, one CPV-2a, and one CPV-2b Argentine strains with respect to international strains reported in the GenBank database. In agreement with previous reports, a high degree of identity was found among CPV-2c Argentine strains (99.6-100% and 99.7-100% at nucleotide and amino acid levels, respectively). However, the appearance of a new substitution in the 440 position (T440A) in four CPV-2c Argentine strains obtained after the year 2009 gives support to the variability observed for this position located within the VP2, three-fold spike. This is the first report on the genetic characterization of the full-length VP2 gene of emerging CPV strains in South America and shows that all the Argentine CPV-2c isolates cluster together with European and North American CPV-2c strains.


Subject(s)
Capsid Proteins/genetics , Dog Diseases/virology , Evolution, Molecular , Parvoviridae Infections/veterinary , Parvovirus, Canine/genetics , Amino Acid Sequence , Animals , Argentina , Asia , Capsid Proteins/chemistry , Dogs , Europe , Female , Genetic Variation , Male , Molecular Sequence Data , Parvoviridae Infections/virology , Parvovirus, Canine/chemistry , Parvovirus, Canine/classification , Parvovirus, Canine/isolation & purification , Phylogeny , Sequence Alignment , South America
3.
Vaccine ; 30(6): 1124-31, 2012 Feb 01.
Article in English | MEDLINE | ID: mdl-22178728

ABSTRACT

Efficient, cost-effective and safe Th1-immunity-inducing vaccine formulations are paramount for achieving protection against Neospora caninum. In this study, a new adjuvant (Providean-AVEC) was used in the development of a N. caninum vaccine and evaluated in a mouse model. Soluble N. caninum tachyzoite native protein extract (sNcAg) was selected as vaccine antigen based on its capacity to activate production of pro-inflammatory cytokines on dendritic cells. Vaccines containing 4 and 0.4 µg of sNcAg, and Providean-AVEC, ISCOM-Matrix or aluminum hydroxide (Alum) were tested in BALB/c mice. While mice vaccinated with 4µg of sNcAg + Providean-AVEC developed specific antibodies shortly after the first dose, the rest of the high antigen payload formulations only induced seroconversion after the booster. Mice immunized with the high payload ISCOM vaccine (4 µg sNcAg) or with either low or high payload Providean-AVEC formulations (0.4 µg and 4 µg sNcAg, respectively) elicited higher IgG2a than IgG1 serum levels, and IFN-γ anamnestic responses with a Th1-cytokine biased profile. These animals had no histological signs of cerebral lesions and parasite burden assessed by quantitative real-time PCR was not detected. Vaccine preparations including Providean-AVEC as adjuvant limited N. canimum multiplication even with only a tenth of antigen payload compared to vaccines containing other adjuvants. Using adjuvants to specifically activate dendritic cells, combined with a careful antigen selection can enhance cellular responses to inert N. caninum vaccines.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Antigens, Protozoan/immunology , Glucans/administration & dosage , Glycine max/chemistry , Lecithins/administration & dosage , Neospora/immunology , Protozoan Vaccines/immunology , Animals , Antibodies, Protozoan/blood , Antigens, Protozoan/isolation & purification , Coccidiosis/prevention & control , Disease Models, Animal , Glucans/isolation & purification , Immunoglobulin G/blood , Interferon-gamma/metabolism , Lecithins/isolation & purification , Leukocytes, Mononuclear/immunology , Mice , Mice, Inbred BALB C , Protozoan Vaccines/administration & dosage , Vaccination/methods
4.
Vet Microbiol ; 133(3): 239-51, 2009 Jan 13.
Article in English | MEDLINE | ID: mdl-18774662

ABSTRACT

Monoclonal antibodies (MAbs) developed against different foot-and-mouth disease virus (FMDV) vaccine strains were extensively used to study any possible antigenic variations during vaccine production in Argentine facilities. Additionally, a typing ELISA using strain specific MAbs was developed to detect potential cross contaminations among FMDV strains in master and working seeds with high specificity and sensitivity and to confirm strains identity in formulated vaccines. This assay was carried out for the South American strains currently in use in production facilities in Argentina (A24/Cruzeiro, A/Argentina/01, O1/Campos and C3/Indaial) and for the strain O/Taiwan, produced only for export to Asia. These non-cross reactive MAbs were also used to analyze the integrity of viral particles belonging to each one of the individual strains, following isolation of 140S virions by means of sucrose density gradients from the aqueous phase of commercial polyvalent vaccines. Antigenic profiles were defined for FMDV reference strains using panels of MAbs, and a coefficient of correlation of reactivity with these panels was calculated to establish consistent identity upon serial passages of master and production seeds. A comparison of vaccine and field strain antigenic profiles performed using coefficients of correlation allowed the rapid identification of two main groups of serotype A viruses collected during the last FMD epidemic in Argentina, whose reactivity matched closely to A/Argentina/2000 and A/Argentina/2001 strains.


Subject(s)
Antibodies, Monoclonal/immunology , Antigens, Viral/classification , Foot-and-Mouth Disease Virus/immunology , Viral Vaccines/immunology , Animals , Antigens, Viral/immunology , Argentina/epidemiology , Cattle , Disease Outbreaks/veterinary , Enzyme-Linked Immunosorbent Assay , Foot-and-Mouth Disease/epidemiology , Foot-and-Mouth Disease/virology , Quality Control
5.
Vaccine ; 26(51): 6577-86, 2008 Dec 02.
Article in English | MEDLINE | ID: mdl-18835312

ABSTRACT

Routine vaccination campaigns are carried out in Argentina twice a year, involving more than 100 million doses of foot-and-mouth disease (FMD) vaccine. Although the challenge test in cattle has not been totally replaced for the assessment of FMD vaccine potency, Argentine Animal Health authorities have used an indirect alternative method based on specific correlation studies of protection against podal generalization (PPG) tests performed in cattle with a validated liquid phase blocking ELISA (lpELISA). The change of vaccine formulations that took place after the 2000-2001 outbreaks, generated a gap in the correlation between lpELISA titers and PPG for the new FMD virus strains. A reappraisal of the correlation between lpELISA titers measured at 60 dpv and virus challenge by the PPG method at 90 dpv, performed for the four virus strains presently included in the Argentine vaccine is presented in this work. The data were obtained from 40 bovine challenge trials (647 sera) performed using exclusive batches of commercial vaccine from the year 2001 to January 2008 for A24/Cruzeiro, A/Argentina/2001, O1/Campos and C3/Indaial FMD virus strains. Curves of percentage of expected protection (EPP) versus lpELISA titers were obtained by logit regression for A/Argentina/2001, O1/Campos and C3/Indaial strains, but not for A24/Cruzeiro strain. The concordance between the direct and indirect tests using an EPP cut off value of 75% (82%, kappa = 0.62), in agreement with data originating from many years of vaccine control in Argentina, remarks the relevance of the acceptance of indirect alternatives to in vivo potency testing.


Subject(s)
Cattle Diseases/prevention & control , Foot-and-Mouth Disease/prevention & control , Viral Vaccines/standards , Animals , Antibodies, Viral/blood , Argentina/epidemiology , Cattle , Cattle Diseases/epidemiology , Cattle Diseases/immunology , Enzyme-Linked Immunosorbent Assay/methods , Foot-and-Mouth Disease/epidemiology , Foot-and-Mouth Disease/immunology , Foot-and-Mouth Disease Virus/immunology , Male , Reproducibility of Results , Sensitivity and Specificity , Viral Vaccines/immunology
6.
Vet Microbiol ; 125(3-4): 341-9, 2007 Dec 15.
Article in English | MEDLINE | ID: mdl-17628358

ABSTRACT

RT-PCR was used to detect canine distemper virus (CDV) RNA in clotted blood from Argentine domestic dogs. The NP gene was detected in 73 out of 99 blood samples analyzed. The deduced amino acid sequence of these gene fragments showed 100% identity with the sequence of other wild-type and vaccine strains. A fragment of the hemagglutinin gene was amplified from 24 (32.9%) of the NP-RNA-positive clinical specimens. These H fragments were further analyzed by restriction fragment length polymorphism (RFLP) and sequencing. A single NdeI site was detected in all 24 wild-type strains but was absent in the vaccine strains. Phylogenetic analysis of the partial hemagglutinin amino acid sequences showed close clustering for local strains, clearly distinct from vaccine strains and other wild-type foreign CDV strains. One of the local strains, Arg 23, branched out of the root of the Argentine clade, close to the European strains, suggesting that two different pathogenic CDV genotypes are currently circulating in Argentina, one of them clearly predominant.


Subject(s)
Distemper Virus, Canine/genetics , Distemper Virus, Canine/isolation & purification , Distemper/virology , Amino Acid Sequence , Animals , Argentina , Base Sequence , Dogs , Female , Hemagglutinins, Viral/chemistry , Hemagglutinins, Viral/genetics , Male , Molecular Sequence Data , Phylogeny , Polymorphism, Restriction Fragment Length , RNA, Bacterial/chemistry , RNA, Bacterial/genetics , Reverse Transcriptase Polymerase Chain Reaction/veterinary , Sequence Alignment
SELECTION OF CITATIONS
SEARCH DETAIL
...